Takeda Heartburn Drug Encounters Delay At U.S. FDA
This article was originally published in PharmAsia News
Executive Summary
A heartburn drug of Takeda's U.S. arm has encountered a snag in its effort to gain approval by the U.S. FDA. The agency notified Takeda Pharmaceuticals of North America it would not be able to complete a review as expected by the end of October. At issue is the TAK-390MR proton pump inhibitor intended for treating gastroesophageal reflux disease and other serious acid-related problems. The agency told Takeda it would need another three months to review all the data supplied by Takeda. A spokesman said Takeda's drug has elements that differ from existing proton pump inhibitors. (Click here for more
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.